Itk Inhibitors
2 drugsAbout Itk
Interleukin-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase crucial for T-cell receptor signaling. As a Tec family kinase, Itk regulates T-cell development, activation, and differentiation through downstream signaling pathways.
While no genetic evidence directly links Itk to specific diseases, its involvement in T-cell function makes it a relevant therapeutic target. Modulating Itk activity may offer therapeutic benefits in immune-related disorders.
Itk is targeted by 2 FDA-approved small molecule drugs, including VOTRIENT (pazopanib hydrochloride). These drugs, marketed by Novartis and NOVUGEN, are primarily used in oncology.
Top Itk Drugs
The Itk drug market is concentrated with Novartis and NOVUGEN holding approved drugs.
High market concentration suggests significant barriers to entry for new competitors.
Itk Drug Modality Landscape
Modalities
Routes of Administration
Itk is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Itk Clinical Trials 153 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Itk. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 49 | 31 | 12 | 6 | 72% |
| Phase 2 | 91 | 60 | 25 | 6 | 71% |
| Phase 3 | 10 | 7 | 0 | 3 | 100% |
| Phase 4 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Itk Drug Approval Timeline (2009 - 2023)
The first Itk-targeting drug was approved in 2009, with the most recent approval in 2023.
The 15-year span between approvals indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 86 (11 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Itk. A trial counts if an approved drug acting on Itk is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.